Non-Hodgkin Lymphoma | Specialty

Dramatic Improvement in NHL Outcomes With CAR T-Cell Versus Standard Therapy

September 20th 2017

Treatment with the autologous anti-CD19 CAR T-cell therapy axicabtagene ciloleucel significantly improved outcomes in refractory non-Hodgkin lymphoma compared with standard therapies.

CAR T-Cell Therapy Active in High-Risk, Refractory CLL

September 20th 2017

Patients with refractory chronic lymphocytic leukemia achieved a high-response rate with CD19-targeted CAR T-cell therapy JCAR014.

Venetoclax Combination Improves PFS in Phase III CLL Trial

September 19th 2017

The combination of venetoclax and rituximab significantly improved progression-free survival compared with rituximab plus bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL),

FDA Approves Copanlisib for Follicular Lymphoma

September 14th 2017

The FDA has granted an accelerated approval to copanlisib (Aliqopa) as a treatment for patients with relapsed follicular lymphoma who have received at least 2 least prior systemic therapies.

FDA Grants Frontline Obinutuzumab Priority Review for Follicular Lymphoma

August 28th 2017

The FDA has granted a priority review to a supplemental biologics license application for obinutuzumab (Gazyva) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with follicular lymphoma.

Dr. Nastoupil on Efficacy With Pembrolizumab and Rituximab in Follicular Lymphoma

August 28th 2017

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses efficacy findings of a study investigating the combination of pembrolizumab (Keytruda) and rituximab (Rituxan) in patients with relapsed follicular lymphoma.

Dr. Andorsky on Next Steps Following MAGNIFY Trial in Follicular Lymphoma

August 24th 2017

David J. Andorsky, MD, medical oncology/hematology, Rocky Mountain Cancer Centers, discusses the next steps of the phase IIIb randomized MAGNIFY study of lenalidomide (Revlimid) plus rituximab (Rituxan) followed by maintenance therapy in relapsed/refractory non-Hodgkin lymphoma, focusing on a cohort of patients with follicular lymphoma.

Dr. Nastoupil on Questions Surrounding TGR1202 in Patients With CLL

August 21st 2017

Loretta J. Nastoupil, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the questions researchers are currently facing with TGR1202 in patients with chronic lymphocytic leukemia (CLL).

FDA Grants Brentuximab Vedotin Priority Review for CTCL

August 16th 2017

The FDA has granted a priority review to a supplemental biologics license application for brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma.

The Future of Treatment in Follicular Lymphoma

August 15th 2017

Novel Therapies in FL: Benefits and Challenges

August 15th 2017

Combination Therapy's Role in Follicular Lymphoma

August 15th 2017

Impact of Copanlisib in Follicular Lymphoma

August 15th 2017

Considering the Value of PI3 Kinase Inhibitors in FL

August 15th 2017

Addressing Unmet Needs in Salvage Therapy for FL

August 15th 2017

The Evolving Landscape of Salvage Therapy for FL

August 15th 2017

Choosing Therapy for Relapsed/Refractory FL

August 15th 2017

Continuing FL Treatment: Maintenance and Surveillance

August 15th 2017

Systemic Treatment for Newly Diagnosed FL

August 15th 2017

Triggers to Initiate Therapy for Follicular Lymphoma

August 15th 2017